Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up

Merck agreed to acquire Terns for $6.7 billion to add a promising leukemia drug candidate, strengthening its oncology pipeline. The deal helps MRK prepare for Keytruda's upcoming patent cliff by diversifying late-stage assets and reducing dependence on the franchise.

Analysis

Merck agreed to acquire Terns for $6.7 billion to add a promising leukemia drug candidate, strengthening its oncology pipeline. The deal helps MRK prepare for Keytruda's upcoming patent cliff by diversifying late-stage assets and reducing dependence on the franchise.